What’s new

• CDSCO approved Enhertu for first-line treatment of HER2-positive metastatic breast cancer in combination with pertuzumab.
• The indication targets roughly 20-25% of India's breast cancer patients, the most common cancer in Indian women.
• Enhertu is a global blockbuster with over $3 billion in annual sales worldwide.

Why it matters

This is a label expansion in a high-prevalence cancer subtype, creating a direct new revenue stream for AstraZeneca India. The company's revenue grew 33% in FY26 on oncology launches; this approval widens the addressable market for its highest-profile drug. The combination with pertuzumab positions Enhertu in the frontline setting, which typically carries longer treatment durations and higher volumes than later-line options.

What we’re watching

• Pricing and reimbursement decisions for the new indication in India.
• Speed of commercial launch and impact on quarterly sales trajectory.
• Whether the frontline approval triggers further label expansions in India.

The full read

AstraZeneca Pharma India just landed its biggest label expansion yet. CDSCO approved Enhertu for first-line HER2-positive metastatic breast cancer, the setting where the largest number of Indian patients are treated. That subgroup, roughly 20-25% of all breast cancer cases in the country, is now eligible for a drug with over $3 billion in annual global sales. The approval pairs Enhertu with pertuzumab and places it squarely in frontline therapy, where treatment durations are longer and volumes are higher than later-line settings. For AstraZeneca India, which posted 33% revenue growth in FY26 on oncology launches, this widens the addressable market for its most important product. The open question is pricing. Enhertu commands premium prices globally; the domestic launch economics will determine how much of the global blockbuster translates into Indian revenue. A mid-cap pharmaceutical company with a ₹20,646 cr market cap now has a frontline oncology asset in the country's most common cancer.

Primary source: BSE · NSE

What’s new

• Revenue rose 33% to ₹22.8 billion.
• Net profit grew to ₹1.9 billion from ₹1.2 billion.
• The company secured 11 regulatory approvals, including its first rare disease therapy, Eculizumab.

Why it matters

AstraZeneca is converting its pipeline into top-line growth through label expansions for established oncology drugs. The 62% profit jump confirms these new indications scale efficiently.

What we’re watching

• Whether the pace of new drug approvals continues in FY27.
• Shareholder response to the proposed ₹36 dividend.
• Contribution of the new rare disease portfolio to margins.

The full read

AstraZeneca Pharma India closed FY26 with ₹22.8 billion in revenue, a 33% increase over the prior year. Profit after tax reached ₹1.9 billion, up from the ₹1.2 billion reported in FY25. The company’s performance relies on its oncology and biopharmaceuticals pipeline, which secured 11 regulatory approvals during the year. These include new indications for Durvalumab, Osimertinib, and Trastuzumab deruxtecan. The company also entered the rare disease market with the launch of Eculizumab.

Growth is accelerating.

The board recommended a final dividend of ₹36 per share, pending shareholder approval. The company is using its existing drug portfolio to capture new market segments, maintaining a strong growth momentum without relying on a single product. The next test is whether the company can maintain this approval pace in the coming year.

Primary source: BSE · NSE

What’s new

• Revenue reached ₹22.8 billion, a 33% increase over the previous year.
• Oncology segment revenue exceeded ₹16 billion.
• The board recommended a final dividend of ₹36 per share.

Why it matters

The company is successfully scaling its high-margin oncology franchise. Profit growth of 62% significantly outpaced revenue growth of 33%.

What we’re watching

• Shareholder approval for the appointment of BSR & Co as statutory auditors.
• Continued sales performance of Durvalumab and Osimertinib.
• The next test is sustaining these margins.

The full read

AstraZeneca Pharma India grew revenue to ₹22.8 billion for the financial year ended March 2026. This represents a 33% increase from the previous year, with the oncology business providing over ₹16 billion of that total. Profit rose to ₹1.9 billion from ₹1.2 billion.

Growth is accelerating.

New indications for Durvalumab and Osimertinib helped the company reach these results, while the board recommended a final dividend of ₹36 per share, up from ₹32 per share, and the company plans to appoint BSR & Co as its new statutory auditors, pending shareholder approval. The next test is whether the company can maintain this pace of expansion in the coming year.

Primary source: BSE · NSE

What’s new

• CDSCO approves Calquence for MCL in combo with bendamustine + rituximab.
• Follows recent CLL/SLL approval; widens patient population.
• Global blockbuster drug now targets aggressive lymphoma with limited options.

Why it matters

MCL is an aggressive lymphoma with few treatment options. This label expansion gives AstraZeneca India a second shot at a premium-priced oncology market and forces analysts to rework revenue forecasts.

What we’re watching

• Speed of launch and pricing strategy for MCL indication.
• Uptake among hematologists given limited alternatives.
• Impact on competition from other BTK inhibitors in India.

The full read

AstraZeneca Pharma India has secured CDSCO approval for its BTK inhibitor Calquence (acalabrutinib) for mantle cell lymphoma, in combination with bendamustine and rituximab, for patients ineligible for autologous stem cell transplant. This is the second Indian nod for Calquence after the recent CLL/SLL approval, and it materially widens the addressable patient population. MCL is an aggressive lymphoma with historically limited options, and Calquence brings a targeted therapy with strong global data. For this mid-cap pharma, each incremental indication creates a new revenue stream in a market where premium-priced oncology drugs are increasingly viable. Analysts will need to update revenue models. The open question is how quickly AstraZeneca can launch and capture share in the competitive BTK inhibitor space.

Primary source: BSE · NSE